Adlai Nortye's H1 2026 results show a strengthened balance sheet with $231.9M in cash, a reduced net loss of $5.3M, and pipeline milestones on track.

summarizeSummary

Adlai Nortye reported H1 2026 financial results with $231.9M in cash, first revenue of $13.1M, and a reduced net loss of $5.3M. Pipeline milestones remain on track with initial data expected in 2027.

check_boxKey Events · Earnings and Guidance · ANL

• Cash Position Strengthened to $231.9M

  Cash and short-term investments reached $231.9 million as of June 30, 2026, up from $8.1 million at year-end 2025, following $140M and $150M private placements in February and April 2026.

• First Revenue of $13.1M

  Revenue of $13.1 million was recognized from the exclusive license agreement with Jiangsu Aosaikang Pharmaceutical for AN9025, primarily from upfront payments and development milestones.

• Net Loss Reduced by 70.9%

  Net loss decreased to $5.3 million for H1 2026 from $18.3 million in H1 2025, driven by revenue recognition and lower R&D expenses.

• Pipeline Milestones on Track

  AN9025 initial Phase Ia data expected in H1 2027; AN4035 first patient dosing expected in H2 2026 with initial data in H2 2027; AN8025 dose escalation completion expected by YE 2026.

auto_awesomeAnalysis · ANL · Life Sciences

Adlai Nortye's first half 2026 results show a dramatically improved financial position with $231.9 million in cash and short-term investments, up from $8.1 million at year-end 2025, driven by two oversubscribed private placements totaling $290 million. The company reported its first revenue of $13.1 million from a license agreement and reduced its net loss by 70.9% to $5.3 million. The pipeline update confirms key milestones remain on track, with initial data for AN9025 expected in H1 2027 and AN4035 dosing expected in H2 2026. The appointment of two leading oncologists to the Scientific Advisory Board strengthens clinical expertise.